Vtesse Inc. has notched new progress toward full enrollment of a pivotal trial of its experimental Niemann-Pick type C1 (NPC) therapy, VTS-270, dosing its first patient in Germany. Read More
PERTH, Australia – A venture capital fund has emerged in Australia that allows new migrants to invest in early stage biomedical companies in the country. Read More
The uptick in Parkinson's disease (PD) programs that began in the first half of this decade is accelerating across the span of drug development, leading to a recent approval, multiple candidates in late-stage development and M&A in the space. Read More
The scrutiny continues of the Medicaid rebate for Mylan NV's Epipen, as the Senate Judiciary Committee seeks more than hearsay on communications between the company and the Centers for Medicare & Medicaid Services (CMS) on whether Epipen qualifies for the noninnovator, or generic, rebate. Read More
As part of its national Precision Medicine Initiative Cohort program, the NIH has expanded a five-year funding award to the Scripps Research Institute from $120 million to $207 million. Read More
Azurrx Biopharma Inc., of New York, lowered the terms for its IPO, and plans to raise $6.6 million by offering 1.2 million shares at a price of $5.50. Read More
Axsome Therapeutics Inc., of New York, highlighted the publication of data showing that AXS-02 (zoledronate) inhibited pain in a rat model of complex regional pain syndrome. Read More
Tocagen Inc., of San Diego, reported updated data for Toca 511 (vocimagene amiretrorepvec) in combination with Toca FC (extended-release 5-flurocytosine) for the treatment of recurrent high-grade glioma at the International Oncolytic Virus Meeting in Vancouver, British Columbia. Read More
